Mineralys Therapeutics, Inc.
MLYS
NASDAQ·Healthcare·Biotechnology·Mkt cap $2.5B
$28.21
▼ -0.21%
P/E
-6.65
Mkt Cap
$2.5B
52-Wk Range
$22.30–$47.65
52-Week Range
$22.30 - $47.65
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 21.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
3 reasons
- Proprietary aldosterone synthase inhibitor with selective mechanism of action
- Focused pipeline targeting unmet needs in resistant hypertension
- Novel therapeutic approach with potential safety and efficacy advantages over existing treatments
Bear Case
1 risk
- Low volatility (beta 0.7).
Growth
Stable outlook
Clinical trial progression and regulatory approval of lorundrostat
Value
Deep value opportunity - significant discount to Biotech & Therapeutics peers
Momentum
Hot
+25.4% over 3m
Quality
Loss-making
Mixed fundamentals
Dividend
None
No dividend
Smart-money signal
Who's buying MLYS right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Nov 9, 2026
AUG 12, 2026
Reported EPS of -$2.85 vs -$0.55 consensus (-419.5% surprise).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-419.5%
Revenue trend · last 8Q
—
—
—
—
—
—
—
—
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$0
$0
$0
$0
$0
$0
$0
$0
Margins · last 8Q
No margin history available.
Wall Street consensus
1 analyst · 100% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
100%
Hold
0%
Sell
0%
Median Price Target
—
Latest: Bank of America · Mar 13, 2026
vs Industry
How MLYS stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related